![Rune Blomhoff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rune Blomhoff
Corporate Officer/Principal bij University of Oslo
Profiel
Rune Blomhoff was the founder of Cgene AS, where he held the title of Chairman in 1985.
Currently, he holds the position of Professor at the University of Oslo.
Actieve functies van Rune Blomhoff
Bedrijven | Functie | Begin |
---|---|---|
University of Oslo | Corporate Officer/Principal | - |
Eerdere bekende functies van Rune Blomhoff
Bedrijven | Functie | Einde |
---|---|---|
Cgene AS
![]() Cgene AS Miscellaneous Commercial ServicesCommercial Services Cgene AS is a holding company that offers contract-based research within the field of in vivo molecular imaging. It is a biotechnology company that has available mice models designed to report real-time gene activity in a living animal, reflecting normal or pathological molecular processes in conditions such as inflammation, infection, oxidative stress, cancer, and cardiovascular disease, hypoxia, and retinoid effects. It develops and makes commercially available new reporter models for in vivo molecular imaging purposes. It also tailors transgenic models to meet specific customer needs. Its reporter models serve as preclinical tool for cost-efficient drug screening by pharmaceutical companies. The company was founded by Harald Carlsen and Rune Blomhoff on April 22, 1985 and is headquartered in Oslo, Norway. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Cgene AS
![]() Cgene AS Miscellaneous Commercial ServicesCommercial Services Cgene AS is a holding company that offers contract-based research within the field of in vivo molecular imaging. It is a biotechnology company that has available mice models designed to report real-time gene activity in a living animal, reflecting normal or pathological molecular processes in conditions such as inflammation, infection, oxidative stress, cancer, and cardiovascular disease, hypoxia, and retinoid effects. It develops and makes commercially available new reporter models for in vivo molecular imaging purposes. It also tailors transgenic models to meet specific customer needs. Its reporter models serve as preclinical tool for cost-efficient drug screening by pharmaceutical companies. The company was founded by Harald Carlsen and Rune Blomhoff on April 22, 1985 and is headquartered in Oslo, Norway. | Commercial Services |